Treatment with Niaspan alone and in combination with BMSC resulted in significantly attenuated BMSC induced Angiogenin and MMP9 expression in the ischemic brain and in the ICA compared to T1DM-MCAo control and BMSC monotherapy treatment group. This evidence concerns the gene MMP9 and type 1 diabetes mellitus.